Kura Oncology, Inc. KURA 深 滬
已收盤 05-08 16:00:00 美东时间
9.42
+0.100
+1.07%
華盛通- 最 高9.51
- 今 開9.35
- 成交量 88.92万股
- 最 低 9.33
- 昨 收 9.32
- 總市值 8.36亿
- 52周最高 12.49
- 市盈率 靜 --
- 換手率 1.00%
- 52周最低 5.45
- 委 比 -18.28%
- 總股本 8876.27万
- 歷史最高 43.00
- 量 比 0.83
- 振 幅 1.93%
- 歷史最低 2.50
- 每 手 1
- 風險率 1.70%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Kyowa Kirin And Kura Oncology Announce First Patient Dosed In Japanese Phase 2 Registrational Clinical Trial Studying Ziftomenib For Treatment Of R/R NPM1-Mutated Acute Myeloid Leukemia
Kyowa Kirin Co., Ltd. (TSE: 4151, "Kyowa Kirin") and Kura Oncology, Inc. (NASDAQ:KURA, "Kura"))) today announced the first patient has been dosed in a Japanese Phase 2 registrational clinical trial (jRCT2031250550)
04-24 20:04
Kura says darlifarnib-cabozantinib trial posts 44% response rate in pretreated ccRCC
Kura says darlifarnib-cabozantinib trial posts 44% response rate in pretreated ccRCC Kura Oncology reported preliminary data from ongoing FIT-001 trial of darlifarnib with cabozantinib in clear cell renal cell carcinoma patients previously treated with cabozantinib. Results were presented at 2026 In
04-17 18:00
美股大行评级 | 小摩上调Bloom Energy目标价从166美元升至231美元；目标价28美元！大摩、高盛等多家机构首予Janus Living(JAN)超配评级
今日重点评级关注：Ascendiant Capital：维持Banzai International"买入"评级，目标价从23美元升至24美元；Ascendiant Capital：维持Synergy CHC Corp."买入"评级，目标价从5美元升至5.5美元
04-15 11:31
Lake Street Initiates Coverage On Kura Oncology with Buy Rating, Announces Price Target of $23
Lake Street analyst Daniel Brims initiates coverage on Kura Oncology (NASDAQ:KURA) with a Buy rating and announces Price Target of $23.
04-14 21:32
Kura Oncology grants inducement stock options for 153,750 shares under 2023 plan
Kura Oncology grants inducement stock options for 153,750 shares under 2023 plan Kura Oncology granted inducement stock options covering 153,750 common shares to six new employees on April 1, 2026. Exercise price set at $8.34 per share. Awards vest over four years, with 25% vesting after one year. R
04-03 19:30
美股大行评级 | 潜在涨幅499.25%！Cabaletta Bio获Guggenheim升目标价至16美元，维持"买入"评级
今日重点评级关注：Guggenheim：维持Cabaletta Bio"买入"评级，目标价从15美元升至16美元；HC Wainwright & Co.：维持Palvella Therapeutics"买入"评级，目标价从255美元升至270美元
03-25 10:31
Mizuho Maintains Outperform on Kura Oncology, Lowers Price Target to $25
Mizuho analyst Mara Goldstein maintains Kura Oncology (NASDAQ:KURA) with a Outperform and lowers the price target from $30 to $25.
03-25 01:11
新浪财经ESG：Kura Oncology Inc MSCI（明晟）ESG评级调降至B
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点击查看【 ESG评级中...
03-24 10:24
美股大行评级 | 韦德布什升美光科技目标价升至500美元，维持"跑赢大市"评级
今日重点评级关注：Piper Sandler：维持Allogene疗法"超配"评级，目标价从7美元升至8美元；B. Riley证券：维持Oncology Institute"买入"评级，目标价从6美元升至8美元
03-16 18:19
